AA are doing DD fundamentally because of Cheyeza East. The rest is just icing on the cake.
Highlights:
· CHDDE060 intersected 1.47% Cu over 39m from 13m
o Includes 2.25% Cu over 10m from 41m
· CHDDE057 intersected 1.78% Cu over 21.50m from 29m
o Includes 2.84% Cu over 11m from 34m
· CHDDE059 intersected 0.76% Cu over 24m from 15m
o Includes 1.70% Cu over 7.50m from 23m
AA certainly aware already and have confirmed they like it.
“Results from both drilling programmes indicate possible large-scale metal discoveries, with further follow up work that we are already progressing. “
That is what it’s all about.
AA due diligence going ahead that is all that matters
Outlook: N4 Pharma is well-positioned to offer developers an alternate delivery approach for their DNA/RNA-based vaccine candidates. Supported by cash from a placing in May, N4P is nearing completion of its COVID-19 programme. Positive results from this project would be a significant milestone for the Group. Through the optimisation programme N4 Pharma looks to progress Nuvec® to a stage where it can seek licencing agreements. We expect interest from potential partners seeking to use Nuvec® as part of their development programme for nucleic acid-based products.
https://www.n4pharma.com/wp-content/uploads/2020/11/2020_SP_Angel_N4P_Initiation_Note_FINAL.pdf
Difficult to buy in volume.
Nuvec, its vaccine / onc. treatment delivery system, can be stored (WHILST loaded with pDNA / mRNA) at room temperature.
The mRNA majors are now aware of Nuvec and will be all over N4P.
The approval itself of Pfizer's vaccine by the UK's MRHA, is also crucial for Nuvec's commercial prospects.
It opens the door for the commercialisation of hundreds of mRNA-based drugs in the future. Nuvec could be a key solution to the delivery issues they face.
Moving upwards again MM’s fleeced a few earlier creating liquidity
MM's dropped the bid to load shares
3 million volume real appetite for shares massively undervalued
Over 1 million volume traded in 8 mins more than on some days
652k traded in 5 mins
Heaving buying into close on Friday as traders exited.
Note Fridays close price 12.50 was near the high 12.75 for the day. Bodes well for the next few sessions and suggests a gap up on open Monday.
Game changing need.
Good luck all
Hugely undervalued for what they have more to come here
Even compared to Hemo this should be 4 times the current mcap
He resigned because of this guy who joined in October:
Arc Minerals Ltd is pleased to announce the appointment of Mr Caleb Mulenga as a Non-Executive Director to its Board of Directors with immediate effect. Mr Mulenga previously spent 8 years at the Development Bank of Zambia, subsequently moving into the private sector and establishing Superior Milling Limited, of which he is currently the Executive Chairman. He currently serves as the Chairman of Access Bank Zambia. Mr Mulenga also holds a bachelor's degree in Business and Economics from the University of Zambia and an MBA from Webster University.
MM’s love trucks to loosen shares and put buyers off no doubt background order being filled
Aeturnum can acquire 100% of KSK for cash consideration of $163m pre IPO (or afterwards for that matter) if they want to. The can acquire the asset at any time!
;o
Plenty of upward trajectory here